Journal article Open Access

Immunotoxin therapy of cancer

Pastan, Ira; Hassan, Raffit; FitzGerald, David J.; Kreitman, Robert J.

Rationally designed anticancer agents that target cell-surface antigens or receptors represent a promising approach for treating cancer patients. However, antibodies that bind these targets are often, by themselves, non-cytotoxic. By attaching potent toxins we can dramatically improve the clinical utility of some anti-tumour antibodies. Here we describe the construction and clinical utility of several recombinant immunotoxins; each of which is composed of antibody Fv fragments fused to powerful bacterial toxins. Results from clinical trials indicate that recombinant immunotoxins and similar agents that are designed to combine antibody selectivity with toxin cell-killing potency will be useful additions to cancer therapy.
Files (352.0 kB)
Name Size
article.pdf
md5:8a8a6b266f43ed436cce8aece9e80d1c
352.0 kB Download
130
211
views
downloads
Views 130
Downloads 211
Data volume 74.3 MB
Unique views 130
Unique downloads 203

Share

Cite as